Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives

Frontiers of Medicine in China

Volumn 4, Issue 4, 2010, Pages 356-362

  Thol, Felicitas ^a   Ganser, Arnold ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

acute myeloid leukemia; mutations; risk stratification

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; MUTATION; REVIEW; RISK ASSESSMENT; TRANSLATIONAL RESEARCH;

GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC TESTING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; MUTATION; RISK ASSESSMENT; TRANSLATIONAL RESEARCH;

EID: 78650691196     PISSN: 16737342     EISSN: 16737458     Source Type: Journal    
DOI: 10.1007/s11684-010-0220-5     Document Type: Review

References (48)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin, 2002, 52(1): 23-47.
2. Rowley J D, Golomb H M, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet, 1977, 1(8010): 549-550.
3. Breems D A, van Putten W L, De Greef G E, van Zelderen-Bhola S L, Gerssen-Schoorl K B, Mellink C H, Nieuwint A, Jotterand M, Hagemeijer A, Beverloo H B, Löwenberg B. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol, 2008, 26(29): 4791-4797.
4. Medeiros B C, Othus M, Fang M, Roulston D, Appelbaum F R. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood, 2010, 116(13): 2224-2228.
5. Byrd J C, Mrózek K, Dodge R K, Carroll A J, Edwards C G, Arthur D C, Pettenati M J, Patil S R, Rao K W, Watson M S, Koduru P R, Moore J O, Stone R M, Mayer R J, Feldman E J, Davey F R, Schiffer C A, Larson R A, Bloomfield C D. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 2002, 100(13): 4325-4336.
6. Dash A, Gilliland D G. Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol, 2001, 14(1): 49-64.
7. Mardis E R, Ding L, Dooling D J, Larson D E, McLellan MD, Chen K, Koboldt D C, Fulton R S, Delehaunty K D, McGrath S D, Fulton L A, Locke D P, Magrini V J, Abbott R M, Vickery T L, Reed J S, Robinson J S, Wylie T, Smith S M, Carmichael L, Eldred J M, Harris C C, Walker J, Peck J B, Du F, Dukes A F, Sanderson G E, Brummett A M, Clark E, McMichael J F, Meyer R J, Schindler J K, Pohl C S, Wallis J W, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert M E, Ivy J V, Kalicki J, Elliott G, Ries R E, Payton J E, Westervelt P, Tomasson M H, Watson M A, Baty J, Heath S, Shannon W D, Nagarajan R, Link D C, Walter M J, Graubert T A, DiPersio J F, Wilson R K, Ley T J. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med, 2009, 361(11): 1058-1066.
8. Chen J, Odenike O, Rowley J D. Leukaemogenesis: more than mutant genes. Nat Rev Cancer, 2010, 10(1): 23-36.
9. Figueroa M E, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos P J, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Greally J M, Valk P J, Löwenberg B, Delwel R, Melnick A. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell, 2010, 17(1): 13-27.
10. American Association for Cancer Research Human Epigenome Task Force; European Union, Network of Excellence, Scientific Advisory Board. Moving AHEAD with an international human epigenome project. Nature, 2008, 454(7205): 711-715.
11. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo R T, Chen P, Wang Y, Yan M, Qian Z, Neilly M B, Jin J, Zhang Y, Bohlander S K, Zhang D E, Larson R A, Le Beau M M, Thirman M J, Golub T R, Rowley J D, Chen J. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A, 2008, 105(40): 15535-15540.
12. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a metaanalysis. Leukemia, 2005, 19(8): 1345-1349.
13. Mead A J, Linch D C, Hills R K, Wheatley K, Burnett A K, Gale R E. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood, 2007, 110(4): 1262-1270.
14. Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer, 2004, 4(5): 394-400.
15. Pabst T, Mueller B U, Zhang P, Radomska H S, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen D G. Dominantnegative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet, 2001, 27(3): 263-270.
16. Pabst T, Eyholzer M, Fos J, Mueller B U. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer, 2009, 100(8): 1343-1346.
17. Wouters B J, Löwenberg B, Erpelinck-Verschueren C A, van Putten W L, Valk P J, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood, 2009, 113(13): 3088-3091.
18. Borer R A, Lehner C F, Eppenberger H M, Nigg E A. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell, 1989, 56(3): 379-390.
19. Falini B, Bolli N, Liso A, Martelli M P, Mannucci R, Pileri S, Nicoletti I. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia, 2009, 23(10): 1731-1743.
20. Schlenk R F, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, O. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med, 2008, 358(18): 1909-1918.
21. Chou WC, Hou H A, Chen C Y, Tang J L, Yao M, Tsay W, Ko B S, Wu S J, Huang S Y, Hsu S C, Chen Y C, Huang Y N, Chang Y C, Lee F Y, Liu M C, Liu C W, Tseng M H, Huang C F, Tien H F. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 2010, 115(14): 2749-2754.
22. Wagner K, Damm F, Göhring G, Görlich K, Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A A, Fiedler W, Kirchner H H, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A, Krauter J. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol, 2010, 28(14): 2356-2364.
23. Paschka P, Schlenk R F, Gaidzik V I, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst H A, Germing U, Döhner H, Döhner K. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol, 2010, 28(22): 3636-3643.
24. Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood, 2010, 116(4): 614-616.
25. Chou WC, Hou H A, Chen C Y, Tang J L, Yao M, Tsay W, Ko B S, Wu S J, Huang S Y, Hsu S C, Chen Y C, Huang Y N, Chang Y C, Lee F Y, Liu M C, Liu C W, Tseng M H, Huang C F, Tien H F. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 2010, 115(14): 2749-2754.
26. Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol, 2010, 28(23): 3717-3723.
27. Marcucci G, Maharry K, Wu Y Z, Radmacher M D, Mrózek K, Margeson D, Holland K B, Whitman S P, Becker H, Schwind S, Metzeler K H, Powell B L, Carter T H, Kolitz J E, Wetzler M, Carroll A J, Baer M R, Caligiuri M A, Larson R A, Bloomfield C D. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol, 2010, 28(14): 2348-2355.
28. Ho P A, Alonzo T A, Kopecky K J, Miller K L, Kuhn J, Zeng R, Gerbing R B, Raimondi S C, Hirsch B A, Oehler V, Hurwitz C A, Franklin J L, Gamis A S, Petersdorf S H, Anderson J E, Reaman G H, Baker L H, Willman C L, Bernstein I D, Radich J P, Appelbaum F R, Stirewalt D L, Meshinchi S. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia, 2010, 24(5): 909-913.
29. Beaupre D M, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol, 1999, 17(3): 1071-1079.
30. Ritter M, Kim T D, Lisske P, Thiede C, Schaich M, Neubauer A. Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia. Haematologica, 2004, 89(11): 1397-1399.
31. Radich J P, Kopecky K J, Willman C L, Weick J, Head D, Appelbaum F, Collins S J. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood, 1990, 76(4): 801-807.
32. Ernst P, Wang J, Korsmeyer S J. The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol, 2002, 9(4): 282-287.
33. Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T, Büchner T, Wörmann B, Hiddemann W, Griesinger F. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia, 2000, 14(5): 796-804.
34. Whitman S P, Ruppert A S, Marcucci G, Mrózek K, Paschka P, Langer C, Baldus C D, Wen J, Vukosavljevic T, Powell B L, Carroll A J, Kolitz J E, Larson R A, Caligiuri M A, Bloomfield C D. Longterm disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood, 2007, 109(12): 5164-5167.
35. Yang L, Han Y, Saurez Saiz F, Minden M D. A tumor suppressor and oncogene: the WT1 story. Leukemia, 2007, 21(5): 868-876.
36. Paschka P, Marcucci G, Ruppert A S, Whitman S P, Mrózek K, Maharry K, Langer C, Baldus C D, Zhao W, Powell B L, Baer M R, Carroll A J, Caligiuri M A, Kolitz J E, Larson R A, Bloomfield C D. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol, 2008, 26(28): 4595-4602.
37. Gaidzik V I, Schlenk R F, Moschny S, Becker A, Bullinger L, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Döhner H, Döhner K. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood, 2009, 113(19): 4505-4511.
38. Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Göhring G, Schlegelberger B, Döhner K, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Döhner H, Heil G, Ganser A, Krauter J. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol, 2010, 28(4): 578-585.
39. Becker H, Marcucci G, Maharry K, Radmacher M D, Mrózek K, Margeson D, Whitman S P, Paschka P, Holland K B, Schwind S, Wu Y Z, Powell B L, Carter T H, Kolitz J E, Wetzler M, Carroll J, Baer M R, Moore J O, Caligiuri M A, Larson R A, Bloomfield C D. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood, 2010, 116(5): 788-792.
40. Marcucci G, Maharry K, Radmacher M D, Mrózek K, Vukosavljevic T, Paschka P, Whitman S P, Langer C, Baldus C D, Liu C G, Ruppert A S, Powell B L, Carroll A J, Caligiuri M A, Kolitz J E, Larson R A, Bloomfield C D. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol, 2008, 26(31): 5078-5087.
41. Green C L, Koo K K, Hills R K, Burnett A K, Linch D C, Gale R E. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol, 2010, 28(16): 2739-2747.
42. Schnittger S, Kohl T M, Haferlach T, Kern W, Hiddemann W, Spiekermann K, Schoch C. KIT-D816 mutations in AML1-ETOpositive AML are associated with impaired event-free and overall survival. Blood, 2006, 107(5): 1791-1799.
43. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, Raffoux E, Leblanc T, Thomas X, Hermine O, Quesnel B, Baruchel A, Leverger G, Dombret H, Preudhomme C, 0, 0. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBFAML). Leukemia, 2006, 20(6): 965-970.
44. Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer R J, Larson R A, Liu E T, Bloomfield C D. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol, 2008, 26(28): 4603-4609.
45. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, Allen C, Green C, Quentmeier H, Drexler H, Burnett A, Linch D, Bonnet D, Lister T A, Fitzgibbon J. Mutation of theWilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol, 2008, 26(33): 5429-5435.
46. Papadaki C, Dufour A, Seibl M, Schneider S, Bohlander S K, Zellmeier E, Mellert G, Hiddemann W, Spiekermann K. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol, 2009, 144(4): 517-523.
47. Bacher U, Badbaran A, Fehse B, Zabelina T, Zander A R, Kröger N. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol, 2009, 37(1): 135-142.
48. Krauter J, Hoellge W, Wattjes M P, Nagel S, Heidenreich O, Bunjes D, Ganser A, Heil G. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes Chromosomes Cancer, 2001, 30(4): 342-348.